Abstract: A mineral fiber forming device including: a centrifuge configured to rotate about a rotation axis, the centrifuge including an annular wall pierced by a plurality of orifices, the axis of symmetry of the annular wall being the rotation axis; a first annular inductor configured to heat a top part of the annular wall; a second annular inductor configured to heat a bottom part of the annular wall. The device makes it possible to increase its energy efficiency and very greatly reduce, even cancel altogether, its carbon dioxide emission level.

Abstract: An article including a glass having that includes SiO2, Al2O3, and B2O3 and least one of Li2O, Na2O, K2O, MgO, CaO, SrO, BaO, SnO2, ZnO, La2O3, F, and Fe2O3, wherein the glass includes a dielectric constant of about 10 or less and/or a loss tangent of about 0.01 or less, both as measured with signals at 10 GHz.

Abstract: The invention relates to a lithium silicate glass ceramic, which contains at least lithium disilicate as a crystal phase, and lithium aluminum silicate as further crystal phase. The lithium silicate glass ceramic in its initial composition contains Al2O3 at 1.5 to 3.5 percent by weight, and K2O at 0.6 to 1.8 percent by weight.

Abstract: A glass article includes a glass substrate, a colored film formed on one of main surfaces of the glass substrate, an uncoated portion where no colored film is formed which is present in part of the one of main surfaces or on an edge face of the glass substrate, a boundary between the colored film and the uncoated portion, and a film thickness varying portion where the colored film gradually tapers in thickness toward the boundary. The uncoated portion is visible in the glass article used as a window, the glass substrate has an absorbance in the wavelength range of 380 nm to 780 nm of 0.10 or lower per mm of thickness, and the glass article has a portion blue in color, gray in color, or pink in color where the colored film is formed.

Abstract: In s glass panel unit, a pitch of pillars is determined such that a distortion of a first panel and second panel is smaller than an interval between the first panel and the second panel. The distortion is calculated based on the interval between the first panel and the second panel, load loading compression fracture per one pillar of the multiple pillars, Young's moduli of the first panel and the second panel, thicknesses of the first panel and the second panel, and Poisson's ratios of the first panel and the second panel.

Abstract: A fluorescent polycarboxylate superplasticizer and a preparation method thereof. The preparation process of the polycarboxylate superplasticizer is as follows. Firstly, a redox radical polymerization is performed on a monomer of an unsaturated acid and a derivative thereof, and an unsaturated polyether monomer to form a polycarboxylate superplasticizer pre-product. Then, the polycarboxylate superplasticizer pre-product is subjected to an esterification reaction with an organic molecule having a fluorescent property to obtain the fluorescent polycarboxylate superplasticizer. The method effectively reduces the reaction difficulty and makes the reaction rapid and efficient. The fluorescent polycarboxylate superplasticizer is non-toxic and non-polluting, and has good controllability in the production process and less side reactions.

Abstract: This rapid-hardening mortar composition includes: a rapid-hardening admixture; cement; and a fine aggregate, wherein the cement is contained in an amount of 100 parts by mass to 2,000 parts by mass with respect to 100 parts by mass of the rapid-hardening admixture, the rapid-hardening admixture is a composition that contains: calcium aluminate; inorganic sulfate in an amount of 50 parts by mass to 200 parts by mass with respect to 100 parts by mass of the calcium aluminate; and a setting modifier in an amount of 0.1 parts by mass to 10 parts by mass with respect to 100 parts by mass of the calcium aluminate, and an average particle diameter of the calcium aluminate is in a range of 8 ?m to 100 ?m, and an average particle diameter of the setting modifier is in a range of 5 ?m or less.

Abstract: A calcium sulphate-based product including gypsum and a shrinkage resistance additive. The shrinkage resistance additive is a metal nitrate, hydroxide, acetate or sulphate and is preferably provided in an amount greater than 4 wt % (based on the amount of additive and gypsum). The additive may be a nitrate of an alkali metal (e.g. potassium), an alkaline earth metal (e.g. magnesium or calcium), a transition metal (e.g. iron or zinc) or aluminium.

Abstract: The present invention provides a calcium sulphate-based product (e.g. a wall board) comprising gypsum, a pozzolan source such as a clay additive, rice husk ash or diatomaceous earth and a metal salt additive. The product may be produced by drying an aqueous slurry comprising calcined gypsum, the pozzolan source and the metal salt additive. The clay additive may be a kaolinitic clay. The metal salt additive may be a magnesium salt e.g. magnesium nitrate, magnesium chloride or magnesium hydroxide.

Abstract: An ultra-stable structural laminate with fire resistance and a lateral nail pull strength from 44 to 300 pounds of force and an insulation R value from 1 to 40, the ultra-stable structural laminate of a cementious material with a nano-molecular veneer and a foam component catalytically reacted into an expanded closed cell foam having a thickness from ?th inch to 8 inches, a density from 1.5 pounds/cubic foot to 3 pounds/cubic foot that self-adheres to the cementitious material forming an ultra-stable structural laminate with fire resistance and a lateral nail pull strength from 44 pounds to 300 pounds of force, an insulation R value from 1 to 40, a resistance to seismic impact for earthquakes over 3.1 on the Richter Scale, a break point from 7 lbs/inch to 100 lbs/inch; and a resistance to wind shear equivalent to a 15 mph downburst.

Abstract: A polyamide powder for selective absorbing sintering, SAS, or selective inhibition sintering, SIS. The polyamide powder has a solution viscosity to ISO 307 of 1.8 to 2 and a rise in the solution viscosity of 0% to 25% when it is subjected to a temperature 20° C. below its melting temperature under air for 20 hours.

Abstract: A method of making a fiber preform for ceramic matrix composite (CMC) fabrication that utilizes a fugitive binder and a machining step is described. The method includes, according to one embodiment, laying up a plurality of plies to form a stack, where each ply comprises an arrangement of fibers. The stack is infiltrated with a polymer at an elevated temperature to form an infiltrated stack that is cooled to form a rigid preform. The rigid fiber preform is machined to have a predetermined shape, such that a machined fiber preform is formed. A composite assembly including the machined fiber preform is formed and then the composite assembly is heated at a sufficient temperature to pyrolyze the polymer. Thus, a porous preform of a predetermined geometry is formed for further processing into a CMC.

Abstract: Various embodiments include methods for densifying a melt infiltrated ceramic matrix composite (CMC) article, and a densified melt infiltrated CMC article formed thereby. Particular embodiments include a method including: providing a porous CMC preform within a first region of a casting apparatus; providing a molten densifier within a pressure head area of a second region of the casting apparatus, the first and second regions being operably connected and the molten densifier including at least one source of silicon; and applying a first pressure to the molten densifier within the pressure head, thereby infiltrating voids within the porous CMC preform with the molten densifier and forming a densified melt infiltrated CMC article.

Abstract: A semi-soluble composite granule may include a homogenous powder including a rock phosphate powder making up about 1.0% to about 99% of the homogenous powder and a hydrolyzed humic acid enriched powder making up about 0.05% to about 25% of the homogenous powder; where the homogenous powder is granulated to form a semi-soluble composite granule; and where the composite granule is between about 0.8 mm and about 4.0 mm in diameter.

Abstract: Provided herein is technology relating to organic fertilizers and particularly, but not exclusively, to organic and/or biodegradable flocculants, methods of preparing organic fertilizers using an organic and/or biodegradable flocculant, and systems for treating water using an organic and/or biodegradable flocculant to prepare an organic fertilizer.

Abstract: Encapsulated seeds, processes for making encapsulated seeds and processes for establishing and improving seed beds and seed bed germination. The encapsulated seeds improve soil productivity through enhancements in soil fertility, soil condition/tilth, and control of soil moisture.

Abstract: The invention relates to a method for converting a gas into methane (CH4) which includes: a step of activating a catalytic material including praseodymium oxide (Pr6O11) associated with nickel oxide (NiO) and alumina (Al2O3), the respective proportions of which are, relative to the total mass of these three compounds: Pr6O11: 1 wt % to 20 wt %, NiO: 1 wt % to 20 wt %, and A12O3: 60 to 98 wt %; and a step of passing a gas including at least one carbon monoxide (CO) over the activated catalytic material.

Abstract: The invention relates to a process for dehydrating alcohols to olefins, comprising a reaction step and a catalyst selectivation step.

Abstract: A catalyst system comprising i) a 2-[(phosphinyl)aminyl] cyclic imine transition metal compound complex and ii) an organoaluminum compound. A process comprising contacting i) ethylene, ii) a catalyst system comprising (a) a 2-[(phosphinyl)aminyl] cyclic imine transition metal compound complex, and (b) an organoaluminum compound, and iii) optionally hydrogen to form an oligomer product.

Abstract: Disclosed are a catalyst system capable of selectively oligomerizing olefins including ethylene and a method for preparing an olefin oligomer by using the same and, specifically, a novel catalyst system capable of trimerizing and tetramerizing olefins, unlike olefin oligomerization catalyst systems that have been reported so far, and a method for preparing an olefin oligomer by using the same. The present invention provides a catalyst system for olefin oligomerization, the catalyst system comprising: a ligand compound represented by chemical formula 1 or 2; a chromium compound; a metal alkyl compound; and an aliphatic or alicyclic hydrocarbon solvent.

Abstract: In the present method a reaction mixture is comprised of a source of adamantane, mixed with an alkane or cycloalkane. A Lewis acid catalyst is added to the reaction mixture which is heated and then purified. The resulting alkyl diamondoid mixtures have significantly higher densities and volumetric net heats of combustion while maintaining low viscosities which allow for use at low temperature.

Abstract: The present invention relates to a process for oxidative coupling of methane (OCM), comprising the steps of: (a) contacting, in a reactor, oxygen and methane with an OCM catalyst, resulting in a reactor effluent comprising ethylene, ethane, methane, carbon dioxide and water; (b) cooling the reactor effluent to obtain a liquid stream comprising water and a gas stream comprising ethylene, ethane, methane and carbon dioxide; (c) removing carbon dioxide from at least a part of the gas stream comprising ethylene, ethane, methane and carbon dioxide resulting in a gas stream comprising ethylene, ethane and methane; (d) passing at least a part of the gas stream comprising ethylene, ethane and methane as obtained in step (c) through a membrane, preferably a membrane comprising metal cations, more preferably a membrane comprising silver (I) ions (Ag+ ions) or copper (I) ions (Cu+ ions), to obtain a stream comprising ethane and a stream comprising ethylene.

Abstract: The present invention provides a production method for indene, comprising a dehydrogenation step of obtaining a reaction product containing indene by contacting a raw material composition containing indene with a dehydrogenation catalyst, wherein the dehydrogenation catalyst comprises a support containing aluminum, and a group 14 metal element and platinum supported on the support, a content of the platinum in the dehydrogenation catalyst is 0.6 to 2.5% by mass based on a whole amount of the dehydrogenation catalyst, and an atomic ratio of the group 14 metal element to the platinum in the dehydrogenation catalyst is 4.0 to 20.0.

Abstract: Provided is a method for producing hexafluoro-1,3-butadiene, and the method can produce hexafluoro-1,3-butadiene at an industrially sufficient level of yield. In a reaction liquid containing a halogenated butane represented by chemical formula, CF2X1—CFX2—CFX3—CF2X4 (X1, X2, X3, and X4 are each independently a halogen atom other than a fluorine atom), zinc, and an organic solvent, a reaction is conducted to eliminate the halogen atoms other than a fluorine atom, X1, X2, X3, and X4, from the halogenated butane, yielding hexafluoro-1,3-butadiene. During the reaction, the concentration of a zinc halide generated by the reaction, in the reaction liquid is not more than the solubility of the zinc halide in the organic solvent.

Abstract: A reactor layout for a process of methanol production from low quality synthesis gas, in which relatively smaller adiabatic reactors can be operated more efficiently, some of the inherent disadvantages of adiabatic reactors for methanol production are avoided. This is done by controlling the outlet temperature in the pre-converter by rapid adjustment of the recycle gas, i.e. by manipulating the gas hourly space velocity in the pre-converter.

Abstract: ?9-Tetrahydrocannabinol (?9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.

Abstract: A method for manufacturing and a method for decolorizing dioctyl terephthalate are provided. The decolorizing dioctyl terephthalate includes: providing an unpurified dioctyl terephthalate; mixing the unpurified dioctyl terephthalate with a reducing agent and an adsorption medium to obtain a first decolorizing product; and mixing the first decolorizing product with a decolorizing adsorbent material to obtain a second decolorizing product. The method for manufacturing dioctyl terephthalate includes: a transesterification step, an alkaline washing and neutralization step, a redox step, a decolorization step and a stripping step; the decolorizing adsorbent material has an acid value between 0.1 and 2 mg KOH/g, a relative humidity between 2 and 10%, and a fineness between 80 and 100 cm2/g.

Abstract: Ester compounds, such as for use in a lubricant, are based on di-, tri- or higher functional carboxylic acids according to formula (I).

Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.

Abstract: Disclosed herein are efflux pump inhibitors and pharmaceutical compositions comprising the same. The efflux pump inhibitors may be used in methods of preventing antibiotic resistance in a subject, and in methods of treating a bacterial infection in a subject. The efflux pump inhibitor may be co-administered with an antibiotic.

Abstract: A compound represented by formula (1) provides a high performance organic electroluminescence device and a novel material for realizing such an organic electroluminescence device: wherein R1 to R6, a to f, L1 to L3, and Ar are as defined in the description.

Abstract: Provided herein are radiolabeled compounds useful for minimally invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for position emission tomography imaging of voltage gated sodium channels. Methods for prepared unlabeled and labeled compounds, and diagnostic methods using the compounds are also provided.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I) is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.

Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

Abstract: The present invention is directed towards novel methods of synthesis of molindone, synthesis of the intermediates of molindone, and high-purity compositions of molindone. In particular, the invention relates to the methods of synthesis of molindone through the Mannich reaction.

Abstract: Provided are a pyridone compound represented by Formula (1): wherein R1 represents a C1-C6 alkyl group which may be substituted, etc., R2 represents a halogen atom, a cyano group, etc., R3 and R4 are independent to each other, and each represents a hydrogen atom, a C1-C6 alkyl group which may be substituted, etc., or in combination with the nitrogen atom to which they are bonded form a pyrrolidinyl group, a piperidinyl group, etc., which may be substituted, Y represents a phenyl group which may be substituted, etc., X represents an oxygen atom or a sulfur atom, and an agricultural and horticultural fungicide containing the same as an active ingredient.

Abstract: The invention relates to a compound chosen from the compounds of formula (I) below, the optical and geometrical isomers thereof and the tautomers thereof, and also the addition salts thereof with an acid or a base, and the solvates thereof: (I). The invention also relates to the use of these particular compounds and the compositions for dyeing keratin fibers.

Abstract: Certain embodiments are directed to small molecule selective inhibitors of the BRD4 bromodomain. Compounds described herein can be used to modulate the bronchiolar NFkB-BRD4 axis, which plays a role in acute neutrophilic response to viral molecular patterns. Compounds described herein can be developed as preventive and therapeutic agents for various human diseases and conditions.

Abstract: The present invention discloses a terpinenol compound as well as its preparation method and application. The structure of such terpinenol compound is as shown in Formula (I) or (II). In Formula (I), R is independently selected from C12-C16 alkyl, —NR1R2, —SR3 or —OR4; R1, R2, R3 and R4 are independently selected from C1-C6 alkyl or —NO2; the C1-C6 alkyl can be substituted by OH; Alternatively, the R1 and R2 form a five-member ring or six-member ring in together with N used to link up them; the five-member or six-member ring may contain one O or C?O. As indicated by results of activity test, such terpinenol compound has satisfactory effect in prevention of asthma, inflammation and pulmonary artery hypertension, which also has high pharmaceutical significance.

Abstract: Disclosed are crystalline salts of Compound I, methods of preparing them, and related pharmaceutical preparations thereof. Also disclosed are methods of treatment using the crystalline salts of the invention.

Abstract: The invention relates to a salt of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1-phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1-phenyl-2-pyrazolin-5-one hemi-napadisylate. These napadisylate salts of edaravone are easy to manufacture and dissolve more rapidly in water than the free edaravone base. In addition, the edaravone salts of the present invention are very stable and easy to handle. The invention also relates to a pharmaceutical composition comprising the aforementioned edaravone salt and to a method of preparing such edaravone salt.

Abstract: Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject. Also provided herein are methods of reducing or preventing the progression of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject.

Abstract: The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma I receptor. The present application is further directed, in part, to methods for treating and/or preventing cancer using compounds disclosed herein, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof.

Abstract: The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof.

Abstract: The present invention provides an oxazine compound having a specific structure, which contains a group having an aromatic ring structure and a plurality of specified carbon-carbon triple bond structure. The present invention further provides a composition containing the oxazine compound having a specific structure of the present invention, a cured product containing the composition, and a laminate having the layer of the cured product. The present invention further still provides a composition for a heat-resistant material and a composition for an electronic material, which contain the composition containing the oxazine compound of the present invention.

Abstract: The present invention provides an oxazine compound having a specific structure, which contains a group having an aromatic ring structure and a plurality of specified carbon-carbon triple bond structure. The present invention further provides a composition containing the oxazine compound having a specific structure of the present invention, a cured product containing the composition, and a laminate having a layer of the cured product. The present invention further still provides a composition for a heat-resistant material and a composition for an electronic material, which contain the composition containing the oxazine compound of the present invention.

Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present invention relates to novel crystal forms of ozanimod. Compared with the prior art, the crystal forms of the present invention have one or more improved properties. The present invention also relates to preparation methods of the crystal forms, pharmaceutical compositions thereof and uses thereof for the manufacture of medicament for treating and/or preventing diseases or adverse conditions associated with modulation, activation, stimulation, inhibition or antagonization of selective sphingosine-1-phosphate (S1P) receptor.

Abstract: The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development.